Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

  • STATUS
    Recruiting
  • End date
    Jan 31, 2025
  • participants needed
    135
  • sponsor
    Weill Medical College of Cornell University
Updated on 31 July 2021
antibiotics
endoscopy
flexible sigmoidoscopy
microbiota
ulcerative colitis
fecal microbiota transplantation
colitis
ulceration

Summary

A double-blind, randomized, placebo-controlled clinical trial examining the efficacy and safety of Fecal Microbiota Transplantation (FMT) and high fiber supplementation in patients with active mild to moderate Ulcerative Colitis (UC). All enrolled subjects will provide serological, stool and mucosal specimen at each clinic visit to help further define the alterations in microbial profiles and immune cell function in response to psyllium fiber after FMT treatment.

Description

This is a randomized, double-blind, placebo-controlled clinical trial with the following treatment assignments:

  1. Investigational FMT (one-time)
  2. Subject will blindly receive investigational FMT once at day 0 colonoscopy
  3. Subjects in this group will blindly receive placebo FMP250 at week 8 by flexible sigmoidoscopy.
  4. Investigational FMT (one-time) + Psyllium (2x/day for 8 weeks)
  5. Subject will blindly receive investigational FMT once at day 0 colonoscopy
  6. Subjects in this group will blindly receive placebo FMP250 at week 8 by flexible sigmoidoscopy.
  7. Placebo FMT (one-time) +/- Psyllium (2x/day for 8 weeks)
  8. Subject will blindly receive placebo FMT once at day 0 colonoscopy
  9. Subjects in this group will blindly receive investigational FMP250 at week 8 by flexible sigmoidoscopy.

Subjects will blindly receive the investigational or placebo FMP250 treatment if they meet all inclusion and exclusion criteria during the day 0 screening colonoscopy. Subjects will receive follow-up phone calls at day 1, week 2, week 6, and week 10 post-FMT and will return for clinic visits at week 4, week 8 and week 12 post-FMT. Stool and blood samples will be collected for research purposes from subjects at every clinic visit (Day 0 colonoscopy, Week 4, Week 8, and Week 12). Mucosal biopsies will also be taken during the initial colonoscopy, at day 0 and during the follow-up flexible sigmoidoscopy at week 8. At week 8 post-FMT, all subjects will be evaluated by flexible sigmoidoscopy. Subjects originally randomized into the placebo cohort at week 0 will receive investigational FMP250 by flexible sigmoidoscopy at week 8, and subjects originally randomized into the investigational cohort at week 0 will receive placebo FMP250 by flexible sigmoidoscopy at week 8. Lastly, all subjects will be contacted for follow-up phone calls every subsequent 6 months for the next year.

Details
Condition Gastroenteritis, Intestinal Diseases, Ulcerative Colitis, Inflammatory bowel disease, Ulcerative Colitis (Pediatric), Bowel Dysfunction, inflammatory bowel diseases
Treatment Fecal Microbiota Transplantation, Psyllium Husk Powder
Clinical Study IdentifierNCT03998488
SponsorWeill Medical College of Cornell University
Last Modified on31 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or Female 18 years of age
Documentation of prior history of mild to moderate UC
Endoscopy confirmed active UC 15 centimeters at week 0 screening colonoscopy
As defined by a total Mayo scoring of 4-10 with an endoscopic sub-score 1
Patients must have a descending intact colon
Patients taking steroid or biologic therapy must be on a stable dose for 4 weeks prior to screening and maintained throughout the trial
Eligible patients willing to undergo screening testing prior to FMT to document baseline status
Urine Testing
Blood Testing
Stool Testing
Patients must discontinue anti-rCDI antibiotics (e.g. vancomycin, fidaxomicin) 48 hours prior to FMT delivery procedure

Exclusion Criteria

Biopsy proven Crohn's disease
UC patients with severe disease (defined as a total mayo score >10)
Clinical complications requiring emergent management (e.g. stricture, bowel obstruction, perforation and/or abscess)
Concurrent C. difficile or other infections
Primary sclerosing cholangitis
Prior history of FMT
Treatment for malignancy within past 5 years
Active or latent tuberculosis
Clinically meaningful laboratory abnormalities
Hb: < 8
ALT: greater than 3x the ULN (upper limit of normal)
History of anaphylactic reactions to food allergens
Subject having any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject participating in the study, would make it unlikely for the subject to complete the study, or would confound the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note